An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Summary

The goal of this prospective single-arm open-label trial is to learn about efficacy and safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The main questions it aims to answer are: * Is Bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis? * Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis? Participants will: * Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total. * Follow-up at weeks 4, 12, and 24, while biosamples will be collected.

Timeline

Start

2023-03-01

Primary completion

2024-06-30

Completion

2024-12-30

Drugs

Indications